[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592472":3},{"organization":4,"armGroups":7,"interventions":38,"overallOfficials":46,"centralContacts":46,"locations":47,"responsibleParty":68,"collaborators":46,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":46,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":46,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":50,"whyStopped":46,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Shenyang Sunshine Pharmaceutical Co., LTD.","INDUSTRY",[8,14,18,22,26,30,34],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1","EXPERIMENTAL","Dose escalation will be conducted using an accelerated titration plus traditional 3+3 design. Dose Escalation includes 7 levels, Q3W IV. Dose extension will be carried out at the selected level. dose level 1 of HBT-708 Q3W i.v.",[13],"Drug: HBT-708",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm 2","Dose escalation will be conducted using an accelerated titration plus traditional 3+3 design. Dose Escalation includes 7 levels, Q3W IV. Dose extension will be carried out at the selected level. dose level 2 of HBT-708 Q3W i.v.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Arm 3","Dose escalation will be conducted using an accelerated titration plus traditional 3+3 design. Dose Escalation includes 7 levels, Q3W IV. Dose extension will be carried out at the selected level. dose level 3 of HBT-708 Q3W i.v.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Arm 4","Dose escalation will be conducted using an accelerated titration plus traditional 3+3 design. Dose Escalation includes 7 levels, Q3W IV. Dose extension will be carried out at the selected level. dose level 4 of HBT-708 Q3W i.v.",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Arm 5","Dose escalation will be conducted using an accelerated titration plus traditional 3+3 design. Dose Escalation includes 7 levels, Q3W IV. Dose extension will be carried out at the selected level. dose level 5 of HBT-708 Q3W i.v.",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"Arm 6","Dose escalation will be conducted using an accelerated titration plus traditional 3+3 design. Dose Escalation includes 7 levels, Q3W IV. Dose extension will be carried out at the selected level. dose level 6 of HBT-708 Q3W i.v.",[13],{"label":35,"type":10,"description":36,"interventionNames":37},"Arm 7","Dose escalation will be conducted using an accelerated titration plus traditional 3+3 design. Dose Escalation includes 7 levels, Q3W IV. Dose extension will be carried out at the selected level. dose level 7 of HBT-708 Q3W i.v.",[13],[39],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"DRUG","HBT-708","bispecific antibody",[9,15,19,23,27,31,35],[45],"SSGJ-708",null,[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Shanghai General Hospital","RECRUITING","Shanghai","Shanghai Municipality","200000","China","CN",{"type":57,"coordinates":58},"Point",[59,60],121.45806,31.22222,{"lat":60,"lon":59},[63],{"name":64,"role":65,"phone":66,"phoneExt":46,"email":67},"Qi Li","CONTACT","13818207333","leeqi2001@hotmail.com",{"type":69,"investigatorFullName":46,"investigatorTitle":46,"investigatorAffiliation":46,"oldNameTitle":46,"oldOrganization":46},"SPONSOR","100592472","phase-1-phase-i-study-of-hbt-708-for-patients-with-advanced-solid-tumors-100592472",false,"NCT06993870","Phase I Study of HBT-708 for Patients With Advanced Solid Tumors","A Phase I Study to Evaluate the Safety, Tolerability, and Initial Efficacy of HBT-708 Monotherapy for Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Male or female subjects, age 18 years or older.\n2. Histologically and\u002For cytologically documented advanced or measurable solid tumors.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Life expectancey \\> = 3 months.\n5. Willingness to provide written informed consent for the study.\n\nExclusion Criteria:\n\n1. Known uncontrolled or symptomatic central nervous system metastatic disease.\n2. Subjects must have recovered (≤ Grade 1 or pretherapy baseline) from AEs due to previously administered therapies. (National Cancer Institute Common terminology Criteria \\[NCI CTCAE\\] v.5.0).\n3. Inadequate organ or bone marrow function.\n4. Pregnant or breast-feeding woman.\n5. Known allergies, hypersensitivity, or intolerance to HBT-708 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","ALL","18 Years","75 Years",{"count":81,"type":82},60,"ESTIMATED","INTERVENTIONAL",[85],"PHASE1","The purpose of this study will be to evaluate the safety, tolerability, and inital efficacy of HBT-708 in subjects with advanced solid tumors.",[88],"Advanced Solid Tumors",[90],"solid tumors","2025-07-08",{"date":93,"type":94},"2025-07-11","ACTUAL",{"date":96,"type":94},"2025-06-16",{"date":98,"type":82},"2027-06-28",{"name":5,"class":6},1]